



EUROPEAN COMMISSION
DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY

Medical Products and Innovation
Veterinary Medicines
Head of Unit

Brussels
SANTE.D.4/LG/ci (2025)12910473

Subject: Request pursuant to Article 141(1)(f) of Regulation (EU) 2019/6

Dear Dr Claassen,

I am writing to you to request the Committee for Veterinary Medicinal Products to provide replies to the set of questions annexed to this letter.

On 19 May 2025, Commission Implementing Regulation (EU) 2025/901 establishing a list of substances which are essential for the treatment of equine species, or which bring added clinical benefit compared to other treatment options available for equine species and for which the withdrawal period for equine species shall be six months and repealing Regulation (EC) No 1950/2006 was adopted.

The need for this request arises from new information recently provided by Member States to the Commission in relation to five substances. That information brings to light elements which warrant consideration from the point of view of the applicable provisions in Commission Implementing Regulation (EU) 2025/901. Given the necessity of ensuring that any subsequent decisions are grounded in the most up-to-date scientific evaluation, the Committee's feedback to the above-mentioned questions is essential.

The Committee's replies to those questions may necessitate amendments to the Annex to Commission Implementing Regulation (EU) 2025/901. Such potential amendments would need to be made within the transitional period provided for in that Regulation in order to ensure legal certainty.

Dr Ivo Claassen
Deputy Executive Director
Head of Veterinary Medicines Division
European Medicines Agency
Domenico Scarlattilaan 6
NL-1083 HS Amsterdam
E-mail: ivo.claassen@ema.europa.eu

In view of that, we would be grateful to receive the replies to the questions no later than **30 April 2026**.

Thank you in advance for your collaboration and invaluable contribution.

Yours sincerely,

(e-signed)
Eva Zamora Escribano

Enclosures: - Questions
- New information provided by MS

c.c.: N. Jarrett, J. Torren Edo (EMA)
A. Las Heras, L. Goranov (SANTE)